enGene (NASDAQ:ENGN) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

enGene (NASDAQ:ENGN) posted its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05, Yahoo Finance reports.

enGene Trading Up 3.1 %

NASDAQ:ENGN opened at $6.70 on Thursday. The company has a quick ratio of 42.80, a current ratio of 42.80 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average price is $7.59 and its two-hundred day moving average price is $11.56. enGene has a 52-week low of $4.94 and a 52-week high of $43.00.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ENGN. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price objective on shares of enGene in a research note on Wednesday. Oppenheimer started coverage on enGene in a research report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.